News

Revance announces addition of fintech platform for aesthetic practices with acquisition of HintMD

Feb 6, 2020

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines Learn More

Jan 13, 2020

DERMATOLOGY TIMES

Revance to introduce TEOXANE RHA® fillers in the U.S. Learn More

Jan 10, 2020

PRACTICAL DERMATOLOGY

Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillers Learn More

Jan 10, 2020

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA Learn More

Jan 9, 2020

Revance Provides Corporate Update and Anticipated Milestones for 2020 Learn More

Dec 5, 2019

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology Learn More

Dec 2, 2019

Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics Learn More

Nov 25, 2019

Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines Learn More

Nov 4, 2019

Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia Learn More

Nov 4, 2019

Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery Learn More

Oct 23, 2019

Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting Learn More

Job Opportunities

Do you have what it takes to join our team? Check out our Careers page and find out.

Latest News:

Job Opportunities

Aesthetics

Therapeutics

Investors

Company

Careers